Last reviewed · How we verify
Methylprednisolone 80 mg
At a glance
| Generic name | Methylprednisolone 80 mg |
|---|---|
| Also known as | Depo-Medrol, Depo-medrol |
| Sponsor | Region Skane |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OMT for Adhesive Capsulitis (PHASE4)
- CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants (PHASE2)
- Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (PHASE1, PHASE2)
- A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence (PHASE2)
- Oral Prednisolone Versus Posterior Sub-Tenon Triamcinolone for Acute Ocular VKH
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis (PHASE3)
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylprednisolone 80 mg CI brief — competitive landscape report
- Methylprednisolone 80 mg updates RSS · CI watch RSS
- Region Skane portfolio CI